01—Abstract
Summary
Summary of the 8-K filed April 30, 2025. Cited figures are marked; the original filing is the authoritative source.
Guardant Health (GH) reported first quarter 2025 results on April 30, 2025, with total revenue of $203.5 milliona, up 21% year over year from $168.5 million.
Growth was broad-based: oncology revenue rose 20% to $150.6 millionb on 25% oncology test volume growth, biopharma & data revenue grew 21% to $45.4 million, and Shield screening contributed $5.7 million from roughly 9,000 tests. Gross margin improved to 63% GAAP (65% non-GAAP) from 61% (63%), and management said Shield and Reveal both reached positive gross margins in the quarter, driven by lower testing costs. Profitability remained negative but improved on a GAAP basis.
GAAP net loss narrowed to $95.2 millionc ($0.77 per share) from $115.0 million ($0.94 per share), aided by a $13.7 million gain on extinguishment of convertible notes and a $7.9 million other income line. Non-GAAP net loss was $61.1 million ($0.49 per share) versus $56.4 million a year earlier, and adjusted EBITDA loss improved slightly to $58.5 million from $61.1 million. Operating expenses rose to $239.8 million GAAP, driven by commercial expansion and the Shield launch.
Free cash flow was negative $67.1 milliond, worse than the prior year's $37.2 million, mainly due to timing of annual bonus payments. Cash, cash equivalents and restricted cash totaled $803.9 million at quarter end, and convertible notes principal fell to $1.09 billion from $1.15 billion. The company raised 2025 revenue guidance to $880-890 million (19-20% growth), up from $850-860 million, with screening revenue guidance lifted to $40-45 million on 52,000-58,000 Shield tests.
Non-GAAP operating expense guidance rose to $830-840 million to fund accelerated Shield commercial buildout, and full-year free cash flow burn is expected at $225-235 million, including about $200 million of screening cash burn. Management expects the non-screening business to reach free cash flow breakeven in Q4 2025. The 8-K is a routine Item 2.02 furnishing of the earnings release; the information is furnished, not filed.
02—Key points
Key Highlights
- Total revenue of $203.5M, up 21% YoY, with oncology test volume up 25% to about 59,000 tests
- 2025 revenue guidance raised to $880-890M (19-20% growth) from $850-860M, with screening guidance lifted to $40-45M
- Shield received ADLT status, setting Medicare pricing at $1,495, and secured first payor coverage from the VA Community Care Network covering over 9 million beneficiaries
- Gross margin improved to 63% GAAP / 65% non-GAAP, and Shield and Reveal both achieved positive gross margins in Q1
- GAAP net loss narrowed to $95.2M from $115.0M, helped by a $13.7M gain on extinguishment of convertible notes; non-GAAP net loss widened slightly to $61.1M
- Free cash flow burn of $67.1M in Q1 versus $37.2M a year earlier, largely due to bonus payment timing; full-year FCF burn guided to $225-235M
- Non-GAAP operating expense guidance raised to $830-840M to accelerate Shield commercial infrastructure, while non-screening business targets FCF breakeven in Q4 2025
03—Questions
Frequently Asked Questions
What drove the revenue beat and guidance raise?
Revenue grew 21% to $203.5M, led by 25% oncology test volume growth and higher reimbursement for Guardant360 and Reveal, plus Shield's first screening revenue. The company raised full-year revenue guidance by $30M at the midpoint, mainly due to higher expected screening revenue from improved salesforce productivity and Shield's ADLT-driven ASP increase.
Is Shield's unit economics improving?
Yes. Management stated that Shield achieved positive gross margin in Q1 2025 due to significant reductions in testing costs, and the ADLT designation increased Medicare pricing to $1,495. However, screening remains a major cash drain, with about $200M of expected 2025 screening net cash burn.
Why did free cash flow worsen year over year?
Q1 2025 free cash flow was negative $67.1M versus negative $37.2M in Q1 2024. The company attributed the difference to timing: the annual bonus was paid in Q1 2025 but in Q2 2024. Full-year FCF burn is still guided to improve to $225-235M from $275M in 2024.
How is the balance sheet and capital structure positioned?
Cash, cash equivalents and restricted cash totaled $803.9M at March 31, 2025. Convertible notes principal decreased to $1.09B from $1.15B, and the company recognized a $13.7M gain on extinguishment of convertible notes. Stockholders' deficit widened to $250.8M, and the company began repurchasing shares, holding 976,351 treasury shares.
Does the 8-K contain anything beyond the earnings release?
No. Item 2.02 furnishes the April 30, 2025 press release (Exhibit 99.1) and Item 9.01 lists the exhibits. The furnished information is not deemed filed under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless specifically referenced.
04—Continue